[{"orgOrder":0,"company":"Taiba Healthcare","sponsor":"Elevar Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"OMAN","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Paclitaxel","moa":"||Microtubule depolymerization","graph1":"Oncology","graph2":"Approved FDF","graph3":"Taiba Healthcare","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiba Healthcare \/ Elevar Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Taiba Healthcare \/ Elevar Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Taiba Healthcare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details : Tiba will be responsible for managing named-patient requests through which physicians can legally and ethically prescribe Apealea for patients prior to commercial availability, commercialize and distribute the product throughout the Middle East and North...

                          Product Name : Apealea

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Undisclosed

                          May 10, 2020

                          Lead Product(s) : Paclitaxel,Carboplatin

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Elevar Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank